key: cord-0732038-r5nzz1j0
authors: Clark, A. E.; Wang, Z.; Cantarel, B. L.; Kanchwala, M.; Xing, C.; Chen, L.; Irwin, P.; Xu, Y.; Oliver, D.; Lee, F.; Gagan, J. R.; Park, J. Y.; Filkins, L.; Muthukumar, A.; Sarode, R.; SoRelle, J. A.
title: Multiplex Fragment Analysis Identifies SARS-CoV-2 Variants
date: 2021-04-16
journal: nan
DOI: 10.1101/2021.04.15.21253747
sha: 70acf1944bff8861c986926fc74dd8b4e0db53d9
doc_id: 732038
cord_uid: r5nzz1j0

The rapid spread of SARS-CoV-2 variants are of critical concern, necessitating systematic efforts for epidemiological surveillance. The current method for identifying variants is viral genome sequencing. Sequencing has multiple limitations to broad clinical adoption including requirements for technical expertise, expense of equipment and bioinformatics, and time for implementation. Here we describe a scalable non-sequencing-based capillary electrophoresis assay to affordably screen variants of SARS-CoV-2. The assay has targets for N1 (CDC nucleocapsid target, internal control), spike gene 69_70 deletion, spike gene 144 deletion, and ORF1A 3675_3677 deletion, which are all present in the B.1.1.7 (UK) variant. ORF1A deletions alone are also present in the New York, Brazil, and South African variants. 648 specimens have been tested to date and the assay is able to detect the B.1.1.7 variant 32 times (n=23 specimens, n=9 positive control replicates). Additionally, the B.1.429 (California) variant can be detected when a 3bp insertion or drop out of the S144 target is present. 7/23 B.1.1.7 specimens have been confirmed by Whole Genome Sequencing (16 pending confirmation), and demonstrate the ability to rapidly track the progression of COVID-19 variants in the population.

time for implementation. Here we describe a scalable, multiplex, non-sequencing-based capillary 35 electrophoresis assay to affordably screen for SARS-CoV-2 VOC. 36 37 38 39 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.15.21253747 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Novel strains of SARS-CoV-2 have emerged with clinically significant genetic mutations. These "variants 41 of concern" VOCs impact transmission kinetics, 1 vaccine responses, 2,3 mortality, 4,5 and drug resistance 42 (monoclonal antibodies). 6-9 Therefore, methods for real-time identification of SARS-CoV-2 VOCs are of exigent 43 need in both clinical and public health arenas. Whole-genome sequencing (WGS) is the current gold standard 44 for SARS-CoV-2 variant identification; however, broad WGS adoption is hampered by cost and requirements 45 for specialized equipment and bioinformatics expertise. 10 While these limitations may be mitigated through 46 centralized high-volume testing, the consequent increased turnaround time for batching, data deconvolution, 47 and sequence analysis exceeds what is clinically actionable for most patient assessments. Therefore, simple, 48 on-site, positive specimen reflex testing for VOCs represents a practical solution. 49

Here, we describe a rapid, cost-effective, and scalable method to detect known VOCs utilizing fragment 50 analysis by capillary electrophoresis in a routine clinical setting. In this procedure, extracted RNA is amplified 51 to create fluorescently-labeled amplicons separated by capillary electrophoresis on a Sanger sequencer. VOCs 52 are then identified by their abnormal amplicon sizes compared to a wild-type reference. By measuring the 53 resultant changes in fragment length, this assay permits a broader range of variant detection compared to 54

primer-probe based RT-qPCR. The reagent and instrumentation requirements for this assay are modest: 55 fluorescently labeled primers, a thermocycler, and Sanger sequencer. Moreover, the time requirement (4 56 hours, Fig. 1B) , simplicity, and cost-effective use of 96-well format support the assay's scalability. Amplicons 57 can be designed up to 500bp in length with up to four fluorescent labels, making the assay adaptable to detect 58 additional SARS-CoV-2 variants as they are identified (Fig. 1C , potential to multiplex to 20-40 targets). This 59 assay therefore allows routine clinical laboratories to rapidly screen SARS-CoV-2 positive specimens for VOCs 60 by a mechanism that can be easily and broadly implemented with limited financial burden or bioinformatic 61 expertise. Real-time monitoring of SARS-CoV-2 VOCs could impact epidemiological tracking and guide clinical 62 management prior to administering monoclonal antibody therapy. 63

For proof of concept, we targeted three deletion mutations initially described in the UK B.1.1.7 VOC. The 64 B.1.1.7 strain was originally discovered due to S-gene target failure (SGTF) secondary to the Spike gene 65

HV69_70del variant in a SARS-CoV-2 commercial assay. 1,5,11 While present in B.1.1.7, the HV69_70del is not 66 specific to this strain (55% of northeast U.S. HV69_70del mutants are not B.1.1.7); 12 therefore, we targeted the 67 S-gene F144 deletion mutation, to improve specificity for B.1.1.7 to >99%. 13 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.15.21253747 doi: medRxiv preprint without S gene deletions is suggestive of the B.1.351, P.1, or B.1.526 VOCs. 17 (Fig. 1A, 2G) . Lastly, the CDC N1 72 primer pair was added as an internal positive control. 73

We validated this method focusing on the principle SARS-CoV-2 VOC impacting European countries and 74 the United States: B.1.1.7. 11 An initial screen of 182 retrospective (12/1/20-1/20/21) and 466 prospective 75 SARS-CoV-2 positive nasopharyngeal specimens (1/25/21-3/11/21) was performed. No VOCs were identified 76 among retrospective specimens (0/182). On the third week in January 2021, the first VOC was identified with 77 characteristic shortened amplicons reflecting B.1.1.7 deletions (Fig 1D, E B.1.1.7 was absent in our patient population before January 2021, but prevalence has steadily increased each 85

week. Using this method, we estimate the weekly prevalence rate to be 28.5% variant occurs. To further destabilize S144R binding to the 22018G>T variant, nucleotides at the 2 nd and 3 rd 92 positions upstream from 3' terminus were mutated. (Fig. 2C, D) . Primer S144_R2'T>G was tested against 4 93 WGS confirmed B.1.429 variants with W152C mutations (Fig. 2H) . However, S144 dropout was not detected 94 for any primer pair. Instead, we detected a single base pair deletion ( Fig. 2A, B) . This was clearest in the primer 95 with the 2 nd upstream nucleotide mutated from T>G (Supplemental Table 1 , S144_R2'T>G). An alternative 96 primer binding configuration skipping the 22018G>T variant could explain the 1 base pair deletion. This 97 aberration provides specificity without loss in sensitivity for California variants, thus demonstrating the assay's 98 flexibility to adapt to emerging strains. 99

When the assay was designed, an isolated ORF1A:del3675_3677 (without S gene deletions) was 100 thought to differentiate P.1 and B.1.351 variants from B.1.1.7 (Fig. 2E, G) . Therefore, when we detected 101 isolated 9 nucleotide deletions in the ORF1A target, these VOCs were suspected (n=5). Interestingly, although 102 WGS confirmed the ORF1A:3675_3677 deletion (Fig. 2I) Fig.2 J,K) and the other two cases as 104 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.15.21253747 doi: medRxiv preprint B.1.241 (N501Y and E484K absent). This recurrence of ORF1A:del3675_3677 in multiple VOC indicates 105 ORF1A:DEL3675_3677 may represent convergent evolution arising in geographically disparate locations. This 106 assay can therefore detect mutations consistent with clinically important SARS-CoV-2 strains, as well as 107 monitor for emerging strains with related genetic alterations. 108

The limit of detection varies by target but ranges from 2,000 copies/ reaction for ORF1A to 62.5 copies/ 109 reaction for all additional targets (Supplemental Table 5 ). Furthermore, as contamination is a concern for PCR 110 reactions with high levels of amplification, this assay can detect the presence of a mixture of WT and mutant 111 DNA by identifying the existence of multiple peaks. 112

Epidemiologic data indicates co-occurrence of the three deletions targeted are present in 95% of 113 B. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.15.21253747 doi: medRxiv preprint Acknowledgements: 127

The authors gratefully acknowledge the technical assistance of Hui Zheng, Huiyu Yao, Emily Ostman, Vanessa 128

Torres and Ginger Koetting. Additionally, we thank Prithvi Raj and Vanessa Schmid for sequencing assistance, 129 and all members of the UTSW COVID diagnostic laboratory for archiving and retrieving specimens. 130 131 .

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.15.21253747 doi: medRxiv preprint found in each Variant of Concern. Lack of the N501Y (J) and E484K (K) mutations precludes classification of this 158 SARS-CoV-2 strain as P.1/ B.1.351. 159

. CC-BY-NC-ND 4.0 International license It is made available under a

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from 161 linking epidemiological and genetic data. medRxiv

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by 164 BNT162b2 vaccine-elicited human sera. bioRxiv

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, 167 convalescent and monoclonal 2 antibodies 3 4 Dami A

Investigation of Novel SARS-CoV-2 Variant Variant of Concern 202012/01 Technical Briefing 5

Covid-19: New UK variant may be linked to increased death rate, early data indicate

Escape of SARS-CoV-2 501Y.V2 variants from neutralization by 175 convalescent plasma. medRxiv

Comprehensive mapping of mutations to the SARS-CoV-2 177 receptor-binding domain that affect recognition by polyclonal human serum antibodies

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from 180 therapeutic 1 antibodies and antibodies induced by infection and vaccination 2 3

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited 183 antibodies

Solutions for surveillance of the S gene mutation in the B.1.1.7 (501Y.V1) SARS-CoV-2 strain lineage -187 Behind the Bench

Genomic epidemiology identifies emergence and rapid 190 transmission of SARS-CoV-2 B.1.1.7 in the United States

S gene dropout patterns in 192 . CC-BY-NC-ND 4.0 International license It is made available under a SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the US. medRxiv

Natural deletions in the SARS-CoV-2 spike glycoprotein drive 195 antibody escape. Science (80-)

Sixteen novel lineages of SARS-CoV-2 in South Africa

Early Release -Genomic Evidence of SARS-CoV-2 Reinfection 199

Involving E484K Spike Mutation

Detection of SARS-CoV-2 RNA by multiplex RT-qPCR. bioRxiv

A dynamic nomenclature proposal for SARS-CoV-2 to assist genomic 204 epidemiology. bioRxiv

Emergence of a Novel SARS-CoV-2 207 Variant in Southern California

Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates 210 of All Major Variants of Concern. medRxiv

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.15.21253747 doi: medRxiv preprint